Placebo News and Research

RSS

Pediatric migraine drugs show limited or no efficacy

There is limited evidence supporting the efficacy of trazodone and topiramate in the prevention of pediatric episodic migraine headaches, show results from a meta-analysis.

30 Jan 2013

Tributyltin exposure may cause ‘transgenerational obesity’

Research shows that offspring of mice exposed to low doses of the chemical tributyltin, used in paints, plastics, and other consumer products, have greater than normal body fat, liver fat, and fat-specific gene expression.

30 Jan 2013

Noninvasive, drugless therapy may help mitigate symptoms associated with neurological conditions

With the infusion of an additional $1 million of financial support from The Susanne Marcus Collins Foundation, Inc., Atlanta, GA, Wake Forest Baptist Medical Center researchers are expanding their studies using a noninvasive, drugless therapy that may help to mitigate symptoms associated with a list of neurological conditions.

30 Jan 2013

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for KYNAMROTM (mipomersen sodium) injection.

30 Jan 2013

Tofacitinib fights rheumatoid arthritis progression

Tofacitinib treats symptoms and prevents structural damage in patients with rheumatoid arthritis who do not respond well to methotrexate, indicate phase III trial findings.

29 Jan 2013

Novel experiment illuminates importance of doctor-patient relationship

A patient's relationship with his or her doctor has long been considered an important component of healing. Now, in a novel investigation in which physicians underwent brain scans while they believed they were actually treating patients, researchers have provided the first scientific evidence indicating that doctors truly can feel their patients' pain - and can also experience their relief following treatment.

29 Jan 2013

Botulinum toxin A does not promote weight loss in obese patients

Despite conflicting data in support of the practice, some overweight Americans looking for an easy fix have turned to gastric botox injections to help them lose weight. This month in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association, researchers from the Mayo Clinic publish a definitive study finding that Botox doesn't promote weight loss.

29 Jan 2013

Cancer risk independent of folic acid supplementation

Folic acid supplementation does not increase or decrease the risk for cancer, suggests research published in The Lancet.

28 Jan 2013

Post-traumatic stress disorder (PTSD) in children: an interview with Donna Gillies

Children with PTSD suffer significant distress or negative impacts on their daily lives. Estimates of the prevalence of PTSD in children and adolescents experiencing trauma are generally very high, at 30% to 40%.

28 Jan 2013

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

28 Jan 2013

Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

Today Biogen Idec released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial, ADVANCE.

28 Jan 2013

FDA accepts Genzyme’s LEMTRADA sBLA for review

Genzyme, a Sanofi Company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental Biologics License Application (sBLA) file seeking approval of LEMTRADA (alemtuzumab) for the treatment of relapsing multiple sclerosis (RMS).

28 Jan 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer.

28 Jan 2013

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

The U.S. Food and Drug Administration today approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets.

28 Jan 2013

Everolimus treatment option for tuberous sclerosis patients

Researchers have shown that the immunosuppressant everolimus provides a potential new treatment option for patients with tuberous sclerosis and associated angiomyolipomas.

25 Jan 2013

Efficacy of docusate called into question

Docusate does not significantly improve the management of constipation in hospice patients, show the results of a randomized, placebo-controlled trial.

25 Jan 2013

Short-term use of folic acid supplements unlikely to increase cancer risk

...

25 Jan 2013

New hope for lupus patients

A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France.

25 Jan 2013

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX).

24 Jan 2013

Placebo News and Research

Pediatric migraine drugs show limited or no efficacy

Tributyltin exposure may cause ‘transgenerational obesity’

Noninvasive, drugless therapy may help mitigate symptoms associated with neurological conditions

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

Tofacitinib fights rheumatoid arthritis progression

Novel experiment illuminates importance of doctor-patient relationship

Botulinum toxin A does not promote weight loss in obese patients

Cancer risk independent of folic acid supplementation

Post-traumatic stress disorder (PTSD) in children: an interview with Donna Gillies

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

FDA accepts Genzyme’s LEMTRADA sBLA for review

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

Everolimus treatment option for tuberous sclerosis patients

Efficacy of docusate called into question

Short-term use of folic acid supplements unlikely to increase cancer risk

New hope for lupus patients

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News